ARRIVENT BIOPHARMA, INC. Retained Earnings
ARRIVENT BIOPHARMA, INC. (AVBP) had Retained Earnings of -$497.85 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$497.85M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$447.96M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$404.64M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$369.10M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$497.85M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$447.96M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$404.64M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$369.10M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$334.12M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$302.72M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$238.33M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$217.70M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$197.14M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$175.26M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$157.84M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |